Your browser doesn't support javascript.
loading
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Pérez-Núñez, Iván; Rozalén, Catalina; Palomeque, José Ángel; Sangrador, Irene; Dalmau, Mariona; Comerma, Laura; Hernández-Prat, Anna; Casadevall, David; Menendez, Silvia; Liu, Daniel Dan; Shen, Minhong; Berenguer, Jordi; Ruiz, Irene Rius; Peña, Raul; Montañés, José Carlos; Albà, M Mar; Bonnin, Sarah; Ponomarenko, Julia; Gomis, Roger R; Cejalvo, Juan Miguel; Servitja, Sonia; Marzese, Diego M; Morey, Lluis; Voorwerk, Leonie; Arribas, Joaquín; Bermejo, Begoña; Kok, Marleen; Pusztai, Lajos; Kang, Yibin; Albanell, Joan; Celià-Terrassa, Toni.
Afiliação
  • Pérez-Núñez I; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Rozalén C; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Palomeque JÁ; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Sangrador I; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Dalmau M; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Comerma L; Pathology Department, Hospital del Mar, Barcelona, Spain.
  • Hernández-Prat A; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Casadevall D; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Menendez S; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Liu DD; Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
  • Shen M; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.
  • Berenguer J; Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
  • Ruiz IR; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Peña R; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Montañés JC; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Albà MM; Research Program on Biomedical Informatics, Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Spain.
  • Bonnin S; Research Program on Biomedical Informatics, Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Spain.
  • Ponomarenko J; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
  • Gomis RR; Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Cejalvo JM; Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Servitja S; Universitat Pompeu Fabra, Barcelona, Spain.
  • Marzese DM; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
  • Morey L; Cancer Science Program, Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Voorwerk L; Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain.
  • Arribas J; Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain.
  • Bermejo B; Medical Oncology Department, Hospital Clínico Universitario; Medicine Department, Universidad de Valencia, Spain, INCLIVA, Valencia, Spain.
  • Kok M; Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain.
  • Pusztai L; Medical Oncology Department, Hospital del Mar, Barcelona, Spain.
  • Kang Y; Fundació Institut d'Investigació Sanitària Illes Balears, Mallorca, Spain.
  • Albanell J; Sylvester Comprehensive Cancer Center, Miami, FL, USA.
  • Celià-Terrassa T; Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL, USA.
Nat Cancer ; 3(3): 355-370, 2022 03.
Article em En | MEDLINE | ID: mdl-35301507
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha